Gamida Cell Ltd. (GMDA) Tops Q3 EPS by 61c

Gamida Cell Ltd. (NASDAQ: GMDA) reported Q3 EPS of $0.30, $0.61 better than the analyst estimate of ($0.31).

“Gamida Cell continued to make strong progress during the quarter. Most importantly, we recently announced that our Phase 3 study of omidubicel met all three secondary endpoints, further underscoring the potential clinical benefit of this novel graft source for bone marrow transplant,” stated Julian Adams, Ph.D., chief executive officer of Gamida Cell. “We look forward to reporting the data in further detail and to initiating the biologics license application (BLA) for omidubicel to the FDA on a rolling basis, both in the fourth quarter of this year.”

“Our second program, GDA-201, a natural killer cell therapy, is also advancing. NK cell immunotherapies offer tremendous potential for transforming the care of hematologic malignancies. Last week, we announced that updated data from the Phase 1 study in patients with non-Hodgkin lymphoma will be presented next month in an oral session at the American Society for Hematology (ASH) annual meeting. The data continue to be compelling, with multiple complete responses and a favorable tolerability profile reported in patients with advanced disease,” Dr. Adams continued.

2020 Financial Guidance

Gamida Cell expects cash used for ongoing operating activities in 2020 to range from $60 million to $65 million.

Gamida Cell expects that its current cash and cash equivalents will support the company’s ongoing operating activities into the second half of 2021. This cash runway guidance is based on the company’s current operational plans and excludes any additional funding and any business development activities that may be undertaken.

For earnings history and earnings-related data on Gamida Cell Ltd. (GMDA) click here.

You May Also Be Interested In

• JPMorgan Upgrades Aviva Plc (AV/:LN) (AIVAF) to Overweight
• ITG (ITG) Tops Q2 EPS by 1c
• North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance